Please login to the form below

Not currently logged in
Email:
Password:

InhibOx launches drug screening database

InhibOx has announced the launch of Scopius-5 - the world's largest currently available drug discovery screening database

InhibOx, the specialist in novel and effective computational methods for drug discovery, today announces the launch of Scopius-5 - the world's largest currently available drug discovery screening database and the first system to pass 100m compounds.

Scopius-5 is a powerful resource that will enable new levels of innovation and rigor to screening processes in drug discovery and is the result of almost 10 years research and investment by InhibOx, aimed to meet the needs of the pharmaceutical and biotech markets for a large, high-value, specialist database to support computer-aided drug discovery processes.

The database platform stores many details of selected compounds, invaluable to those working in drug discovery. They include: multiple-conformation 3D models, shape and charge descriptors, property values and compound availability information, and/or synthetic route details. To ensure their usefulness in discovery projects, entries are filtered against a set of drug-likeness criteria – structural and physical properties known to be common to almost all pharmaceutical compounds.

"InhibOx has developed Scopius-5 platform with associated fast searching technology giving unique capabilities that will allow innovative computer-aided drug discovery services to biotech research operations and support the work of in-house modeling teams in the pharmaceutical sector," said Paul Davie, CEO of InhibOx.

"The lack of a well-curated, high value and searchable database of diverse drug candidate molecules has held-back the success of virtual screening and fragment-based design approaches for many years. The innovations at InhibOx, and the advent of cloud computing to support truly large-scale studies, look set to improve dramatically the effectiveness of these disciplines."

Traditional high-throughput screening (HTS) has proved to be too hit-and-miss, too often; a $2bn industry, which sees an average $1m spend per project, with a less than 50 per cent success rate at finding active leads. Its computational equivalent, virtual screening, if well-designed, should dramatically improve both the costs and hit rates, but too often fails because the data sets used are too restricted in the scope of their chemistry, being based on previous projects, covering different, narrow chemistry requirements. Scopius addresses this problem head on by providing true depth and diversity in its chemistry.

20th December 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete HealthVizion

Complete HealthVizion is a global team of fresh thinkers who aspire to be better every day. We create life-changing medical...

Latest intelligence

Running
A marathon and a sprint
Customer experience is a long-distance race and with pharma late out of the blocks, companies need to put their foot down if they want to compete...
5 tactics to master Market Access
Is it time to rethink your game plan? To succeed at Market Access, follow these 5 tactics:...
Finding the patient voice
How patients feel and speak about clinical trials...

Infographics